23.88% 0.0048

Geovax Labs Inc (GOVXW)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Geovax Labs Inc Stock (GOVXW) Company Profile

Geovax Labs Inc

Healthcare (1168)

Biotechnology (655)

678 384 7220

1900 Lake Park Drive, Suite 380, Smyrna

Prossima data di guadagno

Ultimi documenti SEC

GOVXW's Discussions on Twitter

Confronta GOVXW con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GOVXW Geovax Labs Inc	0.0249	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	473.26	117.98B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	570.58	58.10B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	316.54	42.26B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	565.67	33.42B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	251.57	26.08B	3.81B	-644.79M	-669.77M	-6.24

Geovax Labs Inc Borsa (GOVXW) Ultime notizie

Geovax Labs Inc Azioni (GOVXW) Dati Finanziari

Non sono disponibili dati finanziari per Geovax Labs Inc (GOVXW). Controlla altri titoli per ulteriori informazioni.

Geovax Labs Inc (GOVXW)

Geovax Labs Inc Stock (GOVXW) Company Profile

Confronta GOVXW con altri titoli

Geovax Labs Inc Borsa (GOVXW) Ultime notizie

GeoVax to Present at the Emerging Growth Conference on July 16, 2025 - Yahoo Finance

GeoVax Labs (NASDAQ:GOVX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World

Why Did GeoVax Labs Inc. (GOVX) Soar 10.34%? - AInvest

Roth MKM Keeps Their Buy Rating on GeoVax Labs (GOVX) - The Globe and Mail

Vaccine Co. Secures European Regulatory Breakthrough Potential - streetwisereports.com

GeoVax Labs (NASDAQ:GOVX) Cut to “Sell” at Wall Street Zen - Defense World

GeoVax Labs Announces $6 Million Public Offering - The Globe and Mail

GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives - Yahoo Finance

GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines - citybuzz -

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection - Yahoo Finance

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy - Yahoo Finance

Financial Health Check: Examining Geovax Labs Inc (GOVX)’s Key Ratios - DWinneX

Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Geovax Labs Inc Inc. (GOVX) Price Performance: Is It Undervalued or Overvalued? - investchronicle.com

GeoVax Labs (GOVX) Gains Positive EMA Feedback, Potential Speedier Approval | GOVX Stock News - GuruFocus

GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting - Yahoo Finance

GeoVax Advances Toward European Approval for Mpox and Smallpox Vaccine with EMA's Support - citybuzz -

GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

GeoVax Labs (GOVX) Issues New Stock Units with Warrants | GOVX Stock News - GuruFocus

GeoVax Labs (GOVX) Gains EMA Approval for Phase 3 Vaccine Trial | GOVX Stock News - GuruFocus

GOVX: Geovax Labs Receives Buy Rating from Analyst | GOVX Stock News - GuruFocus

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA - Yahoo Finance

GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025 - citybuzz -

GeoVax to Participate in BIO International Convention 2025 - Yahoo Finance

Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN

GeoVax Advances GEO-MVA Vaccine Development Amid WHO's Mpox Emergency Declaration - citybuzz -

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency - Yahoo Finance

Robinhood Markets, Inc. Reports May 2025 Operating Data - The Globe and Mail

GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress - citybuzz -

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients - Yahoo Finance

42,275 Shares in GeoVax Labs, Inc. (NASDAQ:GOVX) Acquired by Citadel Advisors LLC - Defense World

GeoVax’s Multi-Antigen COVID-19 Vaccine Candidates Show Promise Against Variants - citybuzz -

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia - Yahoo Finance

Northern Trust Corp Invests $29,000 in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World

GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology - Yahoo Finance

GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World

GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing - Yahoo Finance

GeoVax Labs (NASDAQ:GOVX) Shares Up 6.9% – Should You Buy? - Defense World

GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance - Yahoo Finance

GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation - Yahoo Finance

GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations - Yahoo Finance

What caused GOVX's Q2 2024 profit turnaround? - AInvest

GeoVax Labs (GOVX) Projected to Post Earnings on Tuesday - Defense World

GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 - Yahoo Finance

GeoVax Strengthens Patent Portfolio for Innovative Cancer Therapy Approach - citybuzz -

GeoVax Expands Gedeptin(R) Patent Portfolio - Yahoo Finance

GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production - Yahoo Finance

MarketsMedicine Hat News - FinancialContent

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN

D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World

GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Geovax Labs Inc Azioni (GOVXW) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a GOVXW